Cancer - Wiki-Pi

Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide
APC and PPP2CA	adenomatous polyposis coli	protein phosphatase 2, catalytic subunit, alpha isozyme	misspliced GSK3beta mutants stabilize beta-catenin APC truncation mutants have impaired AXIN binding T41 mutants of beta-catenin aren't phosphorylated truncated APC mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP Signaling by Wnt deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Programmed Cell Death Beta-catenin phosphorylation cascade truncations of AMER1 destabilize the destruction complex Apoptotic cleavage of cellular proteins misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Apoptotic execution phase phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated deletions in the AMER1 gene destabilize the destruction complex TCF dependent signaling in response to WNT AMER1 mutants destabilize the destruction complex deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Signaling by GPCR Integration of energy metabolism Signaling by FGFR in disease Mitotic Prophase misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated ERKs are inactivated truncated APC mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP Glycolysis Signaling by Wnt Glucose metabolism Toll Like Receptor TLR1:TLR2 Cascade Degradation of beta-catenin by the destruction complex Toll Like Receptor 5 (TLR5) Cascade RNF mutants show enhanced WNT signaling and proliferation Myoclonic epilepsy of Lafora S33 mutants of beta-catenin aren't phosphorylated AXIN mutants destabilize the destruction complex, activating WNT signaling G1/S Transition Glycogen storage diseases MyD88 dependent cascade initiated on endosome Toll Like Receptor 9 (TLR9) Cascade Beta-catenin phosphorylation cascade Initiation of Nuclear Envelope Reformation Mitotic G1-G1/S phases ERK/MAPK targets Negative regulation of FGFR signaling truncations of AMER1 destabilize the destruction complex misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling TRIF-mediated TLR3/TLR4 signaling Opioid Signalling phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated Spry regulation of FGF signaling Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) Toll Like Receptor 2 (TLR2) Cascade Platelet homeostasis deletions in the AMER1 gene destabilize the destruction complex Platelet sensitization by LDL AMER1 mutants destabilize the destruction complex Resolution of Sister Chromatid Cohesion Toll Like Receptor 3 (TLR3) Cascade Toll Like Receptor 4 (TLR4) Cascade Metabolism of carbohydrates Mitotic G2-G2/M phases Mitotic Metaphase and Anaphase Adaptive Immune System PP2A-mediated dephosphorylation of key metabolic factors MASTL Facilitates Mitotic Progression Mitotic Prometaphase Costimulation by the CD28 family Separation of Sister Chromatids APC truncation mutants have impaired AXIN binding Toll Like Receptor 7/8 (TLR7/8) Cascade G2/M Transition Mitotic Anaphase M Phase Toll Like Receptor TLR6:TLR2 Cascade APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane Activated TLR4 signalling S37 mutants of beta-catenin aren't phosphorylated MyD88 cascade initiated on plasma membrane Cyclin A/B1 associated events during G2/M transition XAV939 inhibits tankyrase, stabilizing AXIN DARPP-32 events MyD88:Mal cascade initiated on plasma membrane TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation Nuclear Envelope Reassembly Innate Immune System Nonsense-Mediated Decay (NMD) E2F mediated regulation of DNA replication ERKs are inactivated Signalling by NGF MAP kinase activation in TLR cascade CTLA4 inhibitory signaling G1 Phase NGF signalling via TRKA from the plasma membrane MyD88-independent cascade Cell Cycle, Mitotic Signaling by FGFR Toll-Like Receptors Cascades Cyclin D associated events in G1 Toll Like Receptor 10 (TLR10) Cascade TCF dependent signaling in response to WNT ERK/MAPK targets deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling MAPK targets/ Nuclear events mediated by MAP kinases Signaling by WNT in cancer Inhibition of replication initiation of damaged DNA by RB1/E2F1 Nuclear Events (kinase and transcription factor activation)
APC and PPP2R5A	adenomatous polyposis coli	protein phosphatase 2, regulatory subunit B, alpha	misspliced GSK3beta mutants stabilize beta-catenin APC truncation mutants have impaired AXIN binding T41 mutants of beta-catenin aren't phosphorylated truncated APC mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP Signaling by Wnt deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Programmed Cell Death Beta-catenin phosphorylation cascade truncations of AMER1 destabilize the destruction complex Apoptotic cleavage of cellular proteins misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Apoptotic execution phase phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated deletions in the AMER1 gene destabilize the destruction complex TCF dependent signaling in response to WNT AMER1 mutants destabilize the destruction complex deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Mitotic Prometaphase Costimulation by the CD28 family Separation of Sister Chromatids misspliced GSK3beta mutants stabilize beta-catenin APC truncation mutants have impaired AXIN binding T41 mutants of beta-catenin aren't phosphorylated truncated APC mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP Mitotic Anaphase Signaling by Wnt M Phase APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane Degradation of beta-catenin by the destruction complex S37 mutants of beta-catenin aren't phosphorylated RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated AXIN mutants destabilize the destruction complex, activating WNT signaling XAV939 inhibits tankyrase, stabilizing AXIN Beta-catenin phosphorylation cascade truncations of AMER1 destabilize the destruction complex misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling CTLA4 inhibitory signaling phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated Cell Cycle, Mitotic Platelet homeostasis deletions in the AMER1 gene destabilize the destruction complex TCF dependent signaling in response to WNT Platelet sensitization by LDL AMER1 mutants destabilize the destruction complex Resolution of Sister Chromatid Cohesion deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer Mitotic Metaphase and Anaphase Adaptive Immune System
APC and CSNK1E	adenomatous polyposis coli	casein kinase 1, epsilon	misspliced GSK3beta mutants stabilize beta-catenin APC truncation mutants have impaired AXIN binding T41 mutants of beta-catenin aren't phosphorylated truncated APC mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP Signaling by Wnt deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Programmed Cell Death Beta-catenin phosphorylation cascade truncations of AMER1 destabilize the destruction complex Apoptotic cleavage of cellular proteins misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Apoptotic execution phase phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated deletions in the AMER1 gene destabilize the destruction complex TCF dependent signaling in response to WNT AMER1 mutants destabilize the destruction complex deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Organelle biogenesis and maintenance misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling G2/M Transition Assembly of the primary cilium Signaling by Wnt Regulation of PLK1 Activity at G2/M Transition Anchoring of the basal body to the plasma membrane Cell Cycle, Mitotic WNT mediated activation of DVL Loss of proteins required for interphase microtubule organizationÂ from the centrosome TCF dependent signaling in response to WNT RNF mutants show enhanced WNT signaling and proliferation Loss of Nlp from mitotic centrosomes XAV939 inhibits tankyrase, stabilizing AXIN Centrosome maturation Signaling by WNT in cancer Mitotic G2-G2/M phases Recruitment of mitotic centrosome proteins and complexes
APC and CSNK2A1	adenomatous polyposis coli	casein kinase 2, alpha 1 polypeptide	misspliced GSK3beta mutants stabilize beta-catenin APC truncation mutants have impaired AXIN binding T41 mutants of beta-catenin aren't phosphorylated truncated APC mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP Signaling by Wnt deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Programmed Cell Death Beta-catenin phosphorylation cascade truncations of AMER1 destabilize the destruction complex Apoptotic cleavage of cellular proteins misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Apoptotic execution phase phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated deletions in the AMER1 gene destabilize the destruction complex TCF dependent signaling in response to WNT AMER1 mutants destabilize the destruction complex deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Mitotic Prometaphase Signal transduction by L1 Axon guidance misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling L1CAM interactions Signaling by Wnt Cell Cycle, Mitotic M Phase WNT mediated activation of DVL TCF dependent signaling in response to WNT RNF mutants show enhanced WNT signaling and proliferation XAV939 inhibits tankyrase, stabilizing AXIN Signaling by WNT in cancer Condensation of Prometaphase Chromosomes		(5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One Resveratrol 1,8-Di-Hydroxy-4-Nitro-Anthraquinone Benzamidine 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone Phosphoaminophosphonic Acid-Adenylate Ester Tetrabromo-2-Benzotriazole DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole 1,2,5,8-tetrahydroxyanthracene-9,10-dione Ellagic Acid
APC and PRKACA	adenomatous polyposis coli	protein kinase, cAMP-dependent, catalytic, alpha	misspliced GSK3beta mutants stabilize beta-catenin APC truncation mutants have impaired AXIN binding T41 mutants of beta-catenin aren't phosphorylated truncated APC mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP Signaling by Wnt deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Programmed Cell Death Beta-catenin phosphorylation cascade truncations of AMER1 destabilize the destruction complex Apoptotic cleavage of cellular proteins misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Apoptotic execution phase phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated deletions in the AMER1 gene destabilize the destruction complex TCF dependent signaling in response to WNT AMER1 mutants destabilize the destruction complex deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Signaling by GPCR Ca-dependent events CaM pathway Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Metabolism of lipids and lipoproteins Integration of energy metabolism Hedgehog 'off' state Phospholipase C-mediated cascade Signaling by FGFR in disease Signaling by EGFRvIII in Cancer Regulation of PLK1 Activity at G2/M Transition PLCG1 events in ERBB2 signaling Gluconeogenesis Glucose metabolism DAP12 signaling Rap1 signalling Myoclonic epilepsy of Lafora Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis Glycogen storage diseases PKA-mediated phosphorylation of key metabolic factors Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell Recruitment of mitotic centrosome proteins and complexes Glucagon signaling in metabolic regulation Signaling by PDGF Calmodulin induced events DAP12 interactions PKA-mediated phosphorylation of CREB Opioid Signalling PKA activation Factors involved in megakaryocyte development and platelet production Aquaporin-mediated transport CREB phosphorylation through the activation of Adenylate Cyclase EGFR interacts with phospholipase C-gamma Signaling by ERBB2 PKA-mediated phosphorylation of CREB Signaling by EGFR Signaling by Interleukins Signaling by VEGF Downstream signal transduction Calmodulin induced events Signaling by EGFR in Cancer Metabolism of carbohydrates PKA activation Interleukin-3, 5 and GM-CSF signaling Mitotic G2-G2/M phases Transmission across Chemical Synapses Adaptive Immune System Organelle biogenesis and maintenance G2/M Transition VEGFA-VEGFR2 Pathway DAG and IP3 signaling CaM pathway Activation of NMDA receptor upon glutamate binding and postsynaptic events Loss of Nlp from mitotic centrosomes Downstream signaling of activated FGFR DARPP-32 events Post NMDA receptor activation events Innate Immune System PKA activation in glucagon signalling Signalling by NGF PLC beta mediated events Vasopressin regulates renal water homeostasis via Aquaporins Regulation of insulin secretion Cytokine Signaling in Immune system Assembly of the primary cilium Signaling by Ligand-Responsive EGFR Variants in Cancer Lipid digestion, mobilization, and transport NGF signalling via TRKA from the plasma membrane G-protein mediated events Signaling by Overexpressed Wild-Type EGFR in Cancer Anchoring of the basal body to the plasma membrane Cell Cycle, Mitotic Signaling by FGFR Loss of proteins required for interphase microtubule organizationÂ from the centrosome PLC-gamma1 signalling Signaling by Hedgehog Degradation of GLI1 by the proteasome Centrosome maturation GLI3 is processed to GLI3R by the proteasome Degradation of GLI2 by the proteasome
APC and ANKRD17	adenomatous polyposis coli	ankyrin repeat domain 17	misspliced GSK3beta mutants stabilize beta-catenin APC truncation mutants have impaired AXIN binding T41 mutants of beta-catenin aren't phosphorylated truncated APC mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP Signaling by Wnt deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Programmed Cell Death Beta-catenin phosphorylation cascade truncations of AMER1 destabilize the destruction complex Apoptotic cleavage of cellular proteins misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Apoptotic execution phase phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated deletions in the AMER1 gene destabilize the destruction complex TCF dependent signaling in response to WNT AMER1 mutants destabilize the destruction complex deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer
APC and CTBP1	adenomatous polyposis coli	C-terminal binding protein 1	misspliced GSK3beta mutants stabilize beta-catenin APC truncation mutants have impaired AXIN binding T41 mutants of beta-catenin aren't phosphorylated truncated APC mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP Signaling by Wnt deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Programmed Cell Death Beta-catenin phosphorylation cascade truncations of AMER1 destabilize the destruction complex Apoptotic cleavage of cellular proteins misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Apoptotic execution phase phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated deletions in the AMER1 gene destabilize the destruction complex TCF dependent signaling in response to WNT AMER1 mutants destabilize the destruction complex deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated Degradation of beta-catenin by the destruction complex S37 mutants of beta-catenin aren't phosphorylated S33 mutants of beta-catenin aren't phosphorylated RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling XAV939 inhibits tankyrase, stabilizing AXIN truncations of AMER1 destabilize the destruction complex misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes deletions in the AMER1 gene destabilize the destruction complex TCF dependent signaling in response to WNT AMER1 mutants destabilize the destruction complex deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer
XIAP and BRCA1	X-linked inhibitor of apoptosis, E3 ubiquitin protein ligase	breast cancer 1, early onset	misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling SMAC binds to IAPs SMAC-mediated dissociation of IAP:caspase complexes SMAC-mediated apoptotic response Signaling by Wnt deactivation of the beta-catenin transactivating complex Apoptotic factor-mediated response TCF dependent signaling in response to WNT RNF mutants show enhanced WNT signaling and proliferation Programmed Cell Death XAV939 inhibits tankyrase, stabilizing AXIN Signaling by WNT in cancer Intrinsic Pathway for Apoptosis	ATM mediated phosphorylation of repair proteins Meiotic recombination Fanconi Anemia pathway ATM mediated response to DNA double-strand break Homologous Recombination Repair Meiotic synapsis Homologous recombination repair of replication-independent double-strand breaks Recruitment of repair and signaling proteins to double-strand breaks Double-Strand Break Repair	1-[3,3-Dimethyl-2-(2-Methylamino-Propionylamino)-Butyryl]-Pyrrolidine-2-Carboxylic Acid(1,2,3,4-Tetrahydro-Naphthalen-1-Yl)-Amide N-METHYLALANYL-3-METHYLVALYL-4-PHENOXY-N-(1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)PROLINAMIDE
APLP1 and CDKN1A	amyloid beta (A4) precursor-like protein 1	cyclin-dependent kinase inhibitor 1A (p21, Cip1)		Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Cellular Senescence p53-Dependent G1/S DNA damage checkpoint Cyclin E associated events during G1/S transition AKT phosphorylates targets in the cytosol Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade G1/S Transition Removal of licensing factors from origins Switching of origins to a post-replicative state Mitotic G1-G1/S phases Signaling by PDGF DAP12 interactions DNA Damage/Telomere Stress Induced Senescence GAB1 signalosome Senescence-Associated Secretory Phenotype (SASP) S Phase Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR SCF(Skp2)-mediated degradation of p27/p21 Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Cyclin A:Cdk2-associated events at S phase entry SCF(Skp2)-mediated degradation of p27/p21 Adaptive Immune System PIP3 activates AKT signaling Orc1 removal from chromatin p53-Dependent G1 DNA Damage Response PI3K events in ERBB2 signaling Transcriptional activation of p53 responsive genes Downstream signaling of activated FGFR G1/S DNA Damage Checkpoints Innate Immune System Transcriptional activation of cell cycle inhibitor p21 Signalling by NGF Synthesis of DNA G1 Phase Regulation of DNA replication Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Cell Cycle, Mitotic Signaling by FGFR Orc1 removal from chromatin Cyclin D associated events in G1 Cell Cycle Checkpoints
APP and CDKN1A	amyloid beta (A4) precursor protein	cyclin-dependent kinase inhibitor 1A (p21, Cip1)	Signaling by GPCR Platelet degranulation Metabolic disorders of biological oxidation enzymes RIP-mediated NFkB activation via ZBP1 Formyl peptide receptors bind formyl peptides and many other ligands Amyloids Toll Like Receptor TLR1:TLR2 Cascade Peptide ligand-binding receptors Toll Like Receptor 5 (TLR5) Cascade The NLRP3 inflammasome Gastrin-CREB signalling pathway via PKC and MAPK Response to elevated platelet cytosolic Ca2+ MyD88 dependent cascade initiated on endosome Toll Like Receptor 9 (TLR9) Cascade G alpha (i) signalling events TRIF-mediated TLR3/TLR4 signaling Toll Like Receptor 2 (TLR2) Cascade G alpha (q) signalling events GPCR downstream signaling Toll Like Receptor 4 (TLR4) Cascade Toll Like Receptor 3 (TLR3) Cascade Platelet activation, signaling and aggregation TAK1 activates NFkB by phosphorylation and activation of IKKs complex Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD) G alpha (q) signalling events Class A/1 (Rhodopsin-like receptors) Toll Like Receptor 7/8 (TLR7/8) Cascade Toll Like Receptor TLR6:TLR2 Cascade DEx/H-box helicases activate type I IFN and inflammatory cytokines production Activated TLR4 signalling MyD88 cascade initiated on plasma membrane ZBP1(DAI) mediated induction of type I IFNs ECM proteoglycans MyD88:Mal cascade initiated on plasma membrane TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation Advanced glycosylation endproduct receptor signaling Innate Immune System Inflammasomes Cytosolic sensors of pathogen-associated DNA MyD88-independent cascade GPCR ligand binding Toll-Like Receptors Cascades RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways Toll Like Receptor 10 (TLR10) Cascade Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways TRAF6 mediated NF-kB activation	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Cellular Senescence p53-Dependent G1/S DNA damage checkpoint Cyclin E associated events during G1/S transition AKT phosphorylates targets in the cytosol Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade G1/S Transition Removal of licensing factors from origins Switching of origins to a post-replicative state Mitotic G1-G1/S phases Signaling by PDGF DAP12 interactions DNA Damage/Telomere Stress Induced Senescence GAB1 signalosome Senescence-Associated Secretory Phenotype (SASP) S Phase Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR SCF(Skp2)-mediated degradation of p27/p21 Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Cyclin A:Cdk2-associated events at S phase entry SCF(Skp2)-mediated degradation of p27/p21 Adaptive Immune System PIP3 activates AKT signaling Orc1 removal from chromatin p53-Dependent G1 DNA Damage Response PI3K events in ERBB2 signaling Transcriptional activation of p53 responsive genes Downstream signaling of activated FGFR G1/S DNA Damage Checkpoints Innate Immune System Transcriptional activation of cell cycle inhibitor p21 Signalling by NGF Synthesis of DNA G1 Phase Regulation of DNA replication Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Cell Cycle, Mitotic Signaling by FGFR Orc1 removal from chromatin Cyclin D associated events in G1 Cell Cycle Checkpoints
APP and TGFBR2	amyloid beta (A4) precursor protein	transforming growth factor, beta receptor II (70/80kDa)	Signaling by GPCR Platelet degranulation Metabolic disorders of biological oxidation enzymes RIP-mediated NFkB activation via ZBP1 Formyl peptide receptors bind formyl peptides and many other ligands Amyloids Toll Like Receptor TLR1:TLR2 Cascade Peptide ligand-binding receptors Toll Like Receptor 5 (TLR5) Cascade The NLRP3 inflammasome Gastrin-CREB signalling pathway via PKC and MAPK Response to elevated platelet cytosolic Ca2+ MyD88 dependent cascade initiated on endosome Toll Like Receptor 9 (TLR9) Cascade G alpha (i) signalling events TRIF-mediated TLR3/TLR4 signaling Toll Like Receptor 2 (TLR2) Cascade G alpha (q) signalling events GPCR downstream signaling Toll Like Receptor 4 (TLR4) Cascade Toll Like Receptor 3 (TLR3) Cascade Platelet activation, signaling and aggregation TAK1 activates NFkB by phosphorylation and activation of IKKs complex Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD) G alpha (q) signalling events Class A/1 (Rhodopsin-like receptors) Toll Like Receptor 7/8 (TLR7/8) Cascade Toll Like Receptor TLR6:TLR2 Cascade DEx/H-box helicases activate type I IFN and inflammatory cytokines production Activated TLR4 signalling MyD88 cascade initiated on plasma membrane ZBP1(DAI) mediated induction of type I IFNs ECM proteoglycans MyD88:Mal cascade initiated on plasma membrane TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation Advanced glycosylation endproduct receptor signaling Innate Immune System Inflammasomes Cytosolic sensors of pathogen-associated DNA MyD88-independent cascade GPCR ligand binding Toll-Like Receptors Cascades RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways Toll Like Receptor 10 (TLR10) Cascade Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways TRAF6 mediated NF-kB activation	Loss of Function of TGFBR2 in Cancer TGFBR2 MSI Frameshift Mutants in Cancer TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer TGFBR2 Kinase Domain Mutants in Cancer Downregulation of TGF-beta receptor signaling SMAD2/3 MH2 Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer TGF-beta receptor signaling activates SMADs TGFBR1 LBD Mutants in Cancer Loss of Function of TGFBR1 in Cancer Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex SMAD4 MH2 Domain Mutants in Cancer		Glycerol
FAS and EGFR	Fas cell surface death receptor	epidermal growth factor receptor	Death Receptor Signalling FasL/ CD95L signaling Programmed Cell Death Extrinsic Pathway	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII		Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib
AR and CDK9	androgen receptor	cyclin-dependent kinase 9	Generic Transcription Pathway Nuclear Receptor transcription pathway	Loss of Function of TGFBR2 in Cancer Formation of HIV-1 elongation complex containing HIV-1 Tat RNA Polymerase II Transcription HIV Infection SMAD2/3 MH2 Domain Mutants in Cancer Tat-mediated elongation of the HIV-1 transcript Tat-mediated HIV elongation arrest and recovery TGFBR1 LBD Mutants in Cancer RNA Polymerase II Pre-transcription Events SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer HIV elongation arrest and recovery HIV Life Cycle Generic Transcription Pathway HIV Transcription Elongation TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer TGFBR2 Kinase Domain Mutants in Cancer Host Interactions of HIV factors Loss of Function of SMAD4 in Cancer Interactions of Tat with host cellular proteins TGFBR1 KD Mutants in Cancer Pausing and recovery of Tat-mediated HIV elongation Loss of Function of TGFBR1 in Cancer Late Phase of HIV Life Cycle Formation of RNA Pol II elongation complex Signaling by TGF-beta Receptor Complex Signaling by TGF-beta Receptor Complex in Cancer Pausing and recovery of HIV elongation Formation of HIV elongation complex in the absence of HIV Tat Transcription of the HIV genome SMAD4 MH2 Domain Mutants in Cancer RNA Polymerase II Transcription Elongation	Levonorgestrel Spironolactone Flutamide Oxandrolone Testosterone Nilutamide Fludrocortisone Drostanolone Nandrolone phenpropionate Bicalutamide Fluoxymesterone Drospirenone Danazol Testosterone Propionate Delta1-dihydrotestosterone Boldenone Calusterone Flufenamic Acid Dihydrotestosterone (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide Methyltrienolone (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE Cyproterone Methyltestosterone 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL Nandrolone decanoate Enzalutamide
AR and SP1	androgen receptor	Sp1 transcription factor	Generic Transcription Pathway Nuclear Receptor transcription pathway	Loss of Function of TGFBR2 in Cancer PPARA activates gene expression Metabolism of lipids and lipoproteins Cellular Senescence SMAD2/3 MH2 Domain Mutants in Cancer TGFBR1 LBD Mutants in Cancer Oncogene Induced Senescence SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Regulation of cholesterol biosynthesis by SREBP (SREBF) Generic Transcription Pathway TGFBR2 MSI Frameshift Mutants in Cancer Fatty acid, triacylglycerol, and ketone body metabolism SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer Loss of Function of TGFBR1 in Cancer Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex Activation of gene expression by SREBF (SREBP) Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) SMAD4 MH2 Domain Mutants in Cancer	Levonorgestrel Spironolactone Flutamide Oxandrolone Testosterone Nilutamide Fludrocortisone Drostanolone Nandrolone phenpropionate Bicalutamide Fluoxymesterone Drospirenone Danazol Testosterone Propionate Delta1-dihydrotestosterone Boldenone Calusterone Flufenamic Acid Dihydrotestosterone (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide Methyltrienolone (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE Cyproterone Methyltestosterone 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL Nandrolone decanoate Enzalutamide
AR and NRIP1	androgen receptor	nuclear receptor interacting protein 1	Generic Transcription Pathway Nuclear Receptor transcription pathway		Levonorgestrel Spironolactone Flutamide Oxandrolone Testosterone Nilutamide Fludrocortisone Drostanolone Nandrolone phenpropionate Bicalutamide Fluoxymesterone Drospirenone Danazol Testosterone Propionate Delta1-dihydrotestosterone Boldenone Calusterone Flufenamic Acid Dihydrotestosterone (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide Methyltrienolone (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE Cyproterone Methyltestosterone 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL Nandrolone decanoate Enzalutamide
AR and ERCC2	androgen receptor	excision repair cross-complementation group 2	Generic Transcription Pathway Nuclear Receptor transcription pathway	RNA Polymerase II Promoter Escape Formation of HIV-1 elongation complex containing HIV-1 Tat Nucleotide Excision Repair RNA Polymerase II Transcription Pre-Initiation And Promoter Opening RNA Polymerase I Chain Elongation RNA Polymerase II Transcription RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription RNA Polymerase I Transcription Initiation RNA Polymerase I Promoter Clearance HIV Infection Formation of the Early Elongation Complex Tat-mediated elongation of the HIV-1 transcript Formation of transcription-coupled NER (TC-NER) repair complex RNA Pol II CTD phosphorylation and interaction with CE RNA Polymerase II Pre-transcription Events Dual incision reaction in TC-NER NoRC negatively regulates rRNA expression HIV Transcription Initiation HIV Life Cycle RNA Pol II CTD phosphorylation and interaction with CE Cytosolic iron-sulfur cluster assembly RNA Polymerase II HIV Promoter Escape HIV Transcription Elongation Dual incision reaction in GG-NER mRNA Capping RNA Polymerase I Transcription RNA Polymerase I Promoter Escape RNA Polymerase I Transcription Termination Epigenetic regulation of gene expression Negative epigenetic regulation of rRNA expression Late Phase of HIV Life Cycle Formation of RNA Pol II elongation complex Global Genomic NER (GG-NER) RNA Polymerase II Transcription Initiation And Promoter Clearance Transcription-coupled NER (TC-NER) Formation of HIV elongation complex in the absence of HIV Tat Formation of the HIV-1 Early Elongation Complex Formation of incision complex in GG-NER RNA Polymerase II Transcription Initiation Transcription of the HIV genome RNA Polymerase II Transcription Elongation	Levonorgestrel Spironolactone Flutamide Oxandrolone Testosterone Nilutamide Fludrocortisone Drostanolone Nandrolone phenpropionate Bicalutamide Fluoxymesterone Drospirenone Danazol Testosterone Propionate Delta1-dihydrotestosterone Boldenone Calusterone Flufenamic Acid Dihydrotestosterone (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide Methyltrienolone (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE Cyproterone Methyltestosterone 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL Nandrolone decanoate Enzalutamide
AR and HDAC4	androgen receptor	histone deacetylase 4	Generic Transcription Pathway Nuclear Receptor transcription pathway	Signaling by NOTCH1 HD Domain Mutants in Cancer Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer Signaling by NOTCH Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant NOTCH1 Intracellular Domain Regulates Transcription Signaling by NOTCH1 Signaling by NOTCH1 PEST Domain Mutants in Cancer Signaling by NOTCH1 in Cancer Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants Constitutive Signaling by NOTCH1 PEST Domain Mutants FBXW7 Mutants and NOTCH1 in Cancer	Levonorgestrel Spironolactone Flutamide Oxandrolone Testosterone Nilutamide Fludrocortisone Drostanolone Nandrolone phenpropionate Bicalutamide Fluoxymesterone Drospirenone Danazol Testosterone Propionate Delta1-dihydrotestosterone Boldenone Calusterone Flufenamic Acid Dihydrotestosterone (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide Methyltrienolone (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE Cyproterone Methyltestosterone 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL Nandrolone decanoate Enzalutamide
AR and STUB1	androgen receptor	STIP1 homology and U-box containing protein 1, E3 ubiquitin protein ligase	Generic Transcription Pathway Nuclear Receptor transcription pathway	Loss of Function of TGFBR2 in Cancer TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Antigen processing: Ubiquitination & Proteasome degradation Loss of Function of SMAD2/3 in Cancer TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer SMAD2/3 MH2 Domain Mutants in Cancer Downregulation of TGF-beta receptor signaling TGFBR1 KD Mutants in Cancer TGF-beta receptor signaling activates SMADs TGFBR1 LBD Mutants in Cancer Loss of Function of TGFBR1 in Cancer Signaling by ERBB2 Signaling by TGF-beta Receptor Complex Signaling by TGF-beta Receptor Complex in Cancer Class I MHC mediated antigen processing & presentation SMAD4 MH2 Domain Mutants in Cancer Adaptive Immune System	Levonorgestrel Spironolactone Flutamide Oxandrolone Testosterone Nilutamide Fludrocortisone Drostanolone Nandrolone phenpropionate Bicalutamide Fluoxymesterone Drospirenone Danazol Testosterone Propionate Delta1-dihydrotestosterone Boldenone Calusterone Flufenamic Acid Dihydrotestosterone (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide Methyltrienolone (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE Cyproterone Methyltestosterone 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL Nandrolone decanoate Enzalutamide
AR and PXN	androgen receptor	paxillin	Generic Transcription Pathway Nuclear Receptor transcription pathway	Cell junction organization GAB1 signalosome Smooth Muscle Contraction Signaling by Ligand-Responsive EGFR Variants in Cancer Signaling by EGFRvIII in Cancer Signaling by Overexpressed Wild-Type EGFR in Cancer VEGFA-VEGFR2 Pathway Signaling by EGFR Signaling by VEGF Regulation of cytoskeletal remodeling and cell spreading by IPP complex components Signaling by EGFR in Cancer Localization of the PINCH-ILK-PARVIN complex to focal adhesions Cell-extracellular matrix interactions	Levonorgestrel Spironolactone Flutamide Oxandrolone Testosterone Nilutamide Fludrocortisone Drostanolone Nandrolone phenpropionate Bicalutamide Fluoxymesterone Drospirenone Danazol Testosterone Propionate Delta1-dihydrotestosterone Boldenone Calusterone Flufenamic Acid Dihydrotestosterone (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide Methyltrienolone (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE Cyproterone Methyltestosterone 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL Nandrolone decanoate Enzalutamide
AR and RUNX1	androgen receptor	runt-related transcription factor 1	Generic Transcription Pathway Nuclear Receptor transcription pathway		Levonorgestrel Spironolactone Flutamide Oxandrolone Testosterone Nilutamide Fludrocortisone Drostanolone Nandrolone phenpropionate Bicalutamide Fluoxymesterone Drospirenone Danazol Testosterone Propionate Delta1-dihydrotestosterone Boldenone Calusterone Flufenamic Acid Dihydrotestosterone (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide Methyltrienolone (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE Cyproterone Methyltestosterone 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL Nandrolone decanoate Enzalutamide

Search Results for: Cancer